로딩 중…
지수 로딩 중…
BUKWANG PHARMACEUTICAL IND CO.,LTD
003000· KOSPI· Health Care· Pharmaceuticals, Biotechnology & Life Sciences
₩4,365-2.13%
2026-06-19
Price Chart
BUKWANG PHARMACEUTICAL IND CO.,LTD+16.40%
Financials
Investment Metrics(as of 2026-06-19)
| Metric | Value |
|---|---|
| Size | |
| Market Cap | 430.67B KRW |
| Revenue | 200.68B KRW |
| Net Income | 5.90B KRW |
| Total Assets | 469.60B KRW |
| Net Assets | 340.93B KRW |
| Employees | 582 |
| Value | |
| P/E | 73.00x |
| P/B | 1.26x |
| PEG | 0.48x |
| P/S | 2.15x |
| EV/EBITDA | 63.37x |
| FCF Yield | -0.51% |
| Profitability | |
| ROE | 1.73% |
| ROA | 1.26% |
| Op. Margin | 3.11% |
| Revenue Growth | -0.06% |
| Earnings Growth | 152.76% |
| Financial Health | |
| Debt Ratio | 137.74% |
| Total Debt | 79.68B KRW |
| FCF | -2.20B KRW |
| Cash | 114.42B KRW |
| Current Ratio | 2.55x |
| Net Debt/EBITDA | -5.56x |
| Dividend | |
| Div. Yield | 2.80% |
| Performance | |
| 1Y Return | 16.40% |
| 1M Return | -15.24% |
| From 52W High | -55.86% |
| 1Y MDD | -57.40% |
| Trading | |
| Volume | 338,700 shares |
| Foreign Own. | 7.64% |
| Per Share | |
| EPS | 153 KRW |
| BPS | 3,380 KRW |
Company Info
Bugwang Pharm, established in 1960 for the purpose of manufacturing and selling pharmaceuticals, was listed on the Securities Market in 1988. The company holds four unlisted subsidiaries, including Denmark-based Contera Pharma A/S, Bugwang Medica Co., Ltd., JaguAHR Therapeutics, and ProteKt Therapeutics. It engages in the manufacturing and sales of pharmaceuticals and quasi-drugs, with major products including Dexid, Ferroba, Legalon, Latuda, and Tasenol. Bugwang Pharm is headquartered in Dongjak-gu, Seoul.